Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Receivables - Net: 2016-2025

Historic Receivables - Net for Akebia Therapeutics (AKBA) over the last 8 years, with Sep 2025 value amounting to $66.2 million.

  • Akebia Therapeutics' Receivables - Net rose 105.85% to $66.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.2 million, marking a year-over-year increase of 105.85%. This contributed to the annual value of $34.4 million for FY2024, which is 12.53% down from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' Receivables - Net is $66.2 million, which was down 9.05% from $72.8 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Receivables - Net registered a high of $82.0 million during Q2 2022, and its lowest value of $18.7 million during Q1 2023.
  • In the last 3 years, Akebia Therapeutics' Receivables - Net had a median value of $32.2 million in 2024 and averaged $38.5 million.
  • In the last 5 years, Akebia Therapeutics' Receivables - Net spiked by 7,268.71% in 2021 and then plummeted by 76.13% in 2023.
  • Over the past 5 years, Akebia Therapeutics' Receivables - Net (Quarterly) stood at $51.6 million in 2021, then declined by 21.90% to $40.3 million in 2022, then fell by 2.47% to $39.3 million in 2023, then decreased by 12.53% to $34.4 million in 2024, then spiked by 105.85% to $66.2 million in 2025.
  • Its Receivables - Net stands at $66.2 million for Q3 2025, versus $72.8 million for Q2 2025 and $61.5 million for Q1 2025.